Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer
Maria Zagorulya, Leon Yim, Duncan M. Morgan, et al.
Immunity (2023) Vol. 56, Iss. 2, pp. 386-405.e10
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity
Mariela A. Moreno Ayala, Timothy F. Campbell, Chen‐Yu Zhang, et al.
Immunity (2023) Vol. 56, Iss. 7, pp. 1613-1630.e5
Open Access | Times Cited: 103
Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity
Siyuan You, Shuqin Li, Lingsu Zeng, et al.
Cancer Cell (2024) Vol. 42, Iss. 8, pp. 1415-1433.e12
Closed Access | Times Cited: 22
Cancer immune evasion, immunoediting and intratumour heterogeneity
Malte Roerden, Stefani Spranger
Nature reviews. Immunology (2025)
Closed Access | Times Cited: 7
Mechanisms and Strategies of Immunosenescence Effects on Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Analysis and Future Directions
Huatao Zhou, Zilong Zheng, Chengming Fan, et al.
Seminars in Cancer Biology (2025) Vol. 109, pp. 44-66
Closed Access | Times Cited: 2
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
Inês Mota, Enrico Patrucco, Cristina Mastini, et al.
Nature Cancer (2023) Vol. 4, Iss. 7, pp. 1016-1035
Closed Access | Times Cited: 27
Same yet different — how lymph node heterogeneity affects immune responses
Paulina Cruz de Casas, Konrad Knöpper, Rupak Dey Sarkar, et al.
Nature reviews. Immunology (2023) Vol. 24, Iss. 5, pp. 358-374
Closed Access | Times Cited: 27
The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
Camille Moeckel, Katrina Bakhl, Ilias Georgakopoulos-Soares, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6710-6710
Open Access | Times Cited: 25
Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors
Lucía López, Luciano Gastón Morosi, Federica La Terza, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
Lymphatic vessels in the age of cancer immunotherapy
Triantafyllia Karakousi, Tenny Mudianto, Amanda W. Lund
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 363-381
Closed Access | Times Cited: 14
Targeting JMJD1C to selectively disrupt tumor Treg cell fitness enhances antitumor immunity
Xuehui Long, Sulin Zhang, Yuliang Wang, et al.
Nature Immunology (2024) Vol. 25, Iss. 3, pp. 525-536
Closed Access | Times Cited: 13
Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells
Yijia Tang, Guangzu Cui, Haicong Liu, et al.
Cancer Communications (2024) Vol. 44, Iss. 6, pp. 601-636
Open Access | Times Cited: 12
Stability and plasticity of regulatory T cells in health and disease
Eugenio Contreras-Castillo, Verónica Yutsil García-Rasilla, María Guadalupe García-Patiño, et al.
Journal of Leukocyte Biology (2024) Vol. 116, Iss. 1, pp. 33-53
Open Access | Times Cited: 10
Expansion of tumor-reactive CD8 + T cell clonotypes occurs in the spleen in response to immune checkpoint blockade
Duncan M. Morgan, Brendan Horton, Vidit Bhandarkar, et al.
Science Immunology (2024) Vol. 9, Iss. 99
Closed Access | Times Cited: 9
Antigen-presenting cells as specialized drivers of intestinal T cell functions
Ranit Kedmi, Dan R. Littman
Immunity (2024) Vol. 57, Iss. 10, pp. 2269-2279
Closed Access | Times Cited: 8
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Jing Wei, Wenke Li, Pengfei Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Vidit Bhandarkar, Teresa Dinter, Stefani Spranger
Science Immunology (2025) Vol. 10, Iss. 103
Closed Access | Times Cited: 1
STING in Cancer Immunoediting: Modeling Tumor-Immune Dynamics Throughout Cancer Development
Xiao Zhang, Yan Chen, Xi Liu, et al.
Cancer Letters (2025) Vol. 612, pp. 217410-217410
Open Access | Times Cited: 1
The tumor-draining lymph node as a reservoir for systemic immune surveillance
Ines Delclaux, Katherine S. Ventre, Dennis Jones, et al.
Trends in cancer (2023) Vol. 10, Iss. 1, pp. 28-37
Open Access | Times Cited: 20
PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice
Elselien Frijlink, Douwe M. T. Bosma, Julia Busselaar, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 6
Open Access | Times Cited: 7
The CD8+ T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects
Willem Van Der Byl, Simone Nüssing, Timothy J. Peters, et al.
Immunity (2024) Vol. 57, Iss. 6, pp. 1324-1344.e8
Closed Access | Times Cited: 7
The histone deacetylase HDAC1 controls dendritic cell development and anti-tumor immunity
Cristiano De Sá Fernandes, Philipp Novoszel, Tommaso Gastaldi, et al.
Cell Reports (2024) Vol. 43, Iss. 6, pp. 114308-114308
Open Access | Times Cited: 6
Epigenetic regulation of human FOXP3+ Tregs: from homeostasis maintenance to pathogen defense
Yi Yue, Yuqing Ren, Chunya Lu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality
Nicolas Guillot, Barnabé Roméo, Shima Sepehri Manesh, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 11, pp. 897-911
Open Access | Times Cited: 16
T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC
Ling Yi, Ziwei Xu, Tianyu Ma, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 6
Open Access | Times Cited: 5
Advances of ultrasound in tumor immunotherapy
Jing Lin, Yu‐Wei Wu, Guangde Liu, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112233-112233
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top